Meeting
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
Authors
Carlo Gambacorti-Passerini
University of Milano-Bicocca, Monza, Italy
Carlo Gambacorti-Passerini , Jeffrey Howard Lipton , Andreas Hochhaus , Vamsi K. Kota , Michele Baccarani , Simon Durrant , Sarit E. Assouline , Dong-Wook Kim , Tim H. Brümmendorf , Eric Leip , Fiona An , Jean Aguiar , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT00261846
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7062)
DOI
10.1200/JCO.2018.36.15_suppl.7062
Abstract #
7062
Poster Bd #
122
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.
First Author: Carlo Gambacorti-Passerini
Poster
2012 ASCO Annual Meeting
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
First Author: Tim H. Brummendorf
Poster
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
First Author: Tony Varughese
Poster
2021 ASCO Annual Meeting
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
First Author: Carlo Gambacorti-Passerini